For how we live.
Both brands sell drug-free external nasal dilators with much the same evidence behind them. The differences are range, materials, and the fact that only one also sells a mouth tape.
In 1,238 people from two community cohorts, apnea severity showed no link to depressive symptoms. Sleep fragmentation did, and that association disappeared once insomnia symptoms entered the model.
The remedies that work are the ones matched to the cause — nose, mouth, tongue or palate. Here is what the trials support, and the sign that means see a doctor first.
In 152 adults tested against two nights of polysomnography, the Galaxy Watch reached an AUROC of 0.94 for moderate-to-severe sleep apnea — with 66.7% specificity at the setting it ships with.
European hypertension specialists found only two wrist-cuff blood pressure watches with validation studies done to established protocols. A sleep group ran a Galaxy Watch against two nights of polysomnography.
A meta-analysis of 27 studies found a dose-response pattern that runs against the nightcap logic: the sedative effect needs a high dose, and the REM disruption starts at a low one.
Tirzepatide has been approved for obstructive sleep apnea since December 2024. A January 2026 reanalysis of the trial behind that approval separates what weight loss fixed from what treating the breathing fixed.
External nasal strips have real, repeatable evidence behind mild snoring relief. They have never been shown to treat sleep apnea, and the two problems are not the same problem.
The practice has real theory behind it and a genuine safety warning attached to it. The studies are small, mostly low quality, and say less than either side of the debate claims.
About a third of adults on two continents wake at least three nights a week. The 7.7% who cannot resume sleep carry almost all of the daytime damage — and the cause is often not what the sleeper thinks.
After four weeks, the comorbid-insomnia group's blood pressure fell 20 points more than the apnea-only group. The finding flips the usual framing of COMISA as simply a worse-outcomes phenotype.
A home-monitoring trial found some patients don't sleep on their backs at home the way they did during their diagnostic sleep study, while others simply failed the vibrating device meant to keep them off their backs.
In 377 patients, hypoxic burden — a metric combining how often, how deep, and how long oxygen drops — tracked with abnormal nighttime blood pressure patterns where conventional measures didn't.
Pooling eight trials, oral appliances left nearly 12 more breathing events per hour than CPAP. But the trials disagreed with each other so much that the researchers say that number itself should be read with caution.
Nearly twice as many CPAP-treated patients saw their HFpEF-like markers improve at one year compared with those who went untreated — in a population sleep specialists have historically deprioritized for treatment.
Orexin antagonists were long avoided in sleep apnea over fears they'd suppress the arousals that end dangerous breathing pauses. Sixteen patients on daridorexant showed no meaningful change in breathing severity.
Women who reported vigorous physical activity had a lower arousal index, less time awake after falling asleep, and more total sleep time. The same association didn't hold for arousal index in men.
The best-validated sleep apnea screener works by being wrong in a specific direction. A 47-study meta-analysis of 26,547 people shows what a questionnaire can and cannot conclude about you.
A 20-point rise in apnea severity tracked with about three times more blood pressure increase in adults with a BMI of 20 than in those with a BMI of 30, flipping a common assumption.
Moderate-to-severe sleep apnea alone roughly doubled all-cause mortality risk. Adding comorbid insomnia to the same patients raised it further — evidence for treating the combination as its own risk category.
Both machine types cut breathing interruptions equally well in a 108-patient study. But auto-adjusting PAP's constantly shifting pressure came with more time awake and less total sleep on night one.
Researchers deliberately withdrew CPAP for three nights to simulate untreated sleep apnea, then tested propranolol against placebo. It slowed the heart-rate surges tied to apnea events, at the price of lighter sleep.
In 2,286 patients with sleep apnea undergoing major surgery, a measure of how deeply and how long oxygen fell — not the apnea-hypopnea index — tracked 30-day cardiovascular events and death.
Breathing through the mouth in sleep tracks closely with sleep apnea severity. The direction of the arrow is the part the research has not settled, and it changes what any intervention can claim.
In a Pennsylvania cohort followed 7.5 years, the combination carried the highest risk when insomnia came with objectively short sleep. Insomnia with normal sleep duration showed no significant association.
Matched against a comparator diabetes drug, incretin agonists were associated with an 8% lower rate of CPAP procedures — alongside a 32% lower mortality that should make readers cautious.